Continuity Biosciences Appoints Josephine Torrente and Dr. Joseph DeSimone to Board of Directors
Continuity Biosciences, a trailblazer in next-generation combination drug delivery systems, has made noteworthy appointments to its board of directors. The company has welcomed Josephine M. Torrente, a director at Hyman, Phelps & McNamara, P.C., and Dr. Joseph M. DeSimone, an entrepreneur and professor at Stanford University. This strategic move aims to enhance Continuity's mission of revolutionizing drug delivery technologies, leveraging their extensive expertise in regulatory affairs and material science innovation.
Josephine M. Torrente
Currently a director at Hyman, Phelps & McNamara, P.C., the largest law firm in the U.S. specializing in FDA regulations, Torrente brings over 30 years of experience advising pharmaceutical and biotechnology companies on regulatory strategies, product development, and lifecycle management. Her profound knowledge of regulations is expected to support Continuity as it enhances its clinical development strategies and collaborates with the FDA in expanding its product pipeline.
Dr. Joseph M. DeSimone
Dr. DeSimone serves as the Sanjiv Sam Gambhir Professor of Translational Medicine and Chemical Engineering at Stanford University. He is a recipient of the National Medal of Technology and Innovation and holds over 200 patents alongside more than 350 scientific publications. Known for being one of the few individuals elected to all three U.S. National Academies (Science, Engineering, and Medicine), Dr. DeSimone co-founded Carbon, known for its CLIP 3D printing process, and founded Focal Medical, which Continuity acquired, along with PinPrint, a strategic investment for 3D micro-dosing technology. His expertise in materials science and drug delivery aligns perfectly with Continuity's goals for localized precision therapeutics.
Bob Whitehead, co-founder and Executive Chairman of Continuity Biosciences, expressed his enthusiasm stating, "We are honored to welcome Josephine and Joe to our board. Josephine's regulatory insight and judgment are unmatched, while Joe not only embodies a visionary perspective on drug delivery but has also been a collaborative force with us through Focal Medical and PinPrint. Their combined expertise is vital as we further scale our programs and create long-term value."
The addition of Torrente and DeSimone brings a wealth of experience to Continuity’s existing board, which also includes Bob Whitehead, Ramakrishna Venugopalan, PhD, MBA, Monica Reed, MD, Mike Fowler, and Allen Weiss. Their collective backgrounds—ranging from leading development roles in major pharmaceutical corporations to directing hospital operations—set a solid foundation for Continuity’s future.
Founded in 2024, Continuity Biosciences focuses on developing advanced delivery platforms for biologics and complex therapeutics, emphasizing precision targeting and tailor-made release. With operations in Houston, Texas, Raleigh, North Carolina, Bradenton, Florida, and Turin, Italy, the company has a diverse portfolio spanning oncology, metabolic diseases, infectious diseases, and women’s health. Through strategic acquisitions like Focal Medical and targeted investments such as PinPrint, Continuity aims to build a differentiated platform that innovates the delivery of complex therapeutics.
Appointee Profiles
Josephine M. Torrente
Currently a director at Hyman, Phelps & McNamara, P.C., the largest law firm in the U.S. specializing in FDA regulations, Torrente brings over 30 years of experience advising pharmaceutical and biotechnology companies on regulatory strategies, product development, and lifecycle management. Her profound knowledge of regulations is expected to support Continuity as it enhances its clinical development strategies and collaborates with the FDA in expanding its product pipeline.
Dr. Joseph M. DeSimone
Dr. DeSimone serves as the Sanjiv Sam Gambhir Professor of Translational Medicine and Chemical Engineering at Stanford University. He is a recipient of the National Medal of Technology and Innovation and holds over 200 patents alongside more than 350 scientific publications. Known for being one of the few individuals elected to all three U.S. National Academies (Science, Engineering, and Medicine), Dr. DeSimone co-founded Carbon, known for its CLIP 3D printing process, and founded Focal Medical, which Continuity acquired, along with PinPrint, a strategic investment for 3D micro-dosing technology. His expertise in materials science and drug delivery aligns perfectly with Continuity's goals for localized precision therapeutics.
Company Commentary
Bob Whitehead, co-founder and Executive Chairman of Continuity Biosciences, expressed his enthusiasm stating, "We are honored to welcome Josephine and Joe to our board. Josephine's regulatory insight and judgment are unmatched, while Joe not only embodies a visionary perspective on drug delivery but has also been a collaborative force with us through Focal Medical and PinPrint. Their combined expertise is vital as we further scale our programs and create long-term value."
The addition of Torrente and DeSimone brings a wealth of experience to Continuity’s existing board, which also includes Bob Whitehead, Ramakrishna Venugopalan, PhD, MBA, Monica Reed, MD, Mike Fowler, and Allen Weiss. Their collective backgrounds—ranging from leading development roles in major pharmaceutical corporations to directing hospital operations—set a solid foundation for Continuity’s future.
About Continuity Biosciences
Founded in 2024, Continuity Biosciences focuses on developing advanced delivery platforms for biologics and complex therapeutics, emphasizing precision targeting and tailor-made release. With operations in Houston, Texas, Raleigh, North Carolina, Bradenton, Florida, and Turin, Italy, the company has a diverse portfolio spanning oncology, metabolic diseases, infectious diseases, and women’s health. Through strategic acquisitions like Focal Medical and targeted investments such as PinPrint, Continuity aims to build a differentiated platform that innovates the delivery of complex therapeutics.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.